Noxopharm’s Veyonda to Begin First-Line Sarcoma Treatment Testing
11 May 2021 - 10:30PM
Business Wire
FDA IND Approval Leads to CEP-2 Kickoff
Australian clinical-stage drug development company Noxopharm
Limited (ASX:NOX) today announced its CEP-2 study will begin
shortly. CEP-2 is related to the Investigational New Drug (IND)
approval of Veyonda® by the FDA based on evidence that Veyonda may
increase generally poor response rates of sarcoma cancers to
chemotherapy in combination with common chemotherapy drug,
doxorubicin, for patients with soft tissue sarcomas. The
announcement marks the Company’s commitment to act on this valuable
opportunity with the appointment of a contract research
organization to oversee the study.
Sarcoma was deliberately selected as a rare cancer carrying
important funding and regulatory approval benefits including
seven-year exclusive marketing opportunities. Sarcomas have very
limited treatment options with only an estimated 14% of soft tissue
sarcomas responding to chemotherapy. The Company is confident that
Veyonda, with its unique mix of immunotherapy actions, has the
means to increase both survival and response rates significantly
when combined with doxorubicin.
“Soft tissue sarcomas are in that basket of cancers where there
has been remarkably little advance in survival statistics over the
past few decades, and the horizon has appeared to hold little
reason to think that would change,” said Graham Kelly, CEO of
Noxopharm. “What we have seen to date with Veyonda both
pre-clinically and clinically gives us confidence that a
combination of Veyonda and doxorubicin has the capacity to deliver
that change.”
About Noxopharm
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug
development company focused on the treatment of cancer and septic
shock. Veyonda® is the Company’s first pipe-line drug candidate
currently in Phase 2 clinical trialling. Veyonda has two main drug
actions — a moderating effect on the
ceramide/sphingosine-1-phosphate balance and inhibition of STING
signalling. Activity against the former target contributes to its
dual-acting oncotoxic and immuno-oncology functions designed to
enhance the effectiveness and safety of standard oncology
treatments, i.e., chemotherapies, radiotherapy, and immune
checkpoint inhibitors. Activity against the latter target provides
an anti-inflammatory effect, also contributing to an anti-cancer
action, but also potentially blocking septic shock.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210511005097/en/
Jane Byram SCORR Marketing 512-626-2758
jane@scorrmarketing.com
Noxopharm (ASX:NOX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Noxopharm (ASX:NOX)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Noxopharm Limited (Australian Stock Exchange): 0 recent articles
More Noxopharm Fpo News Articles